(ALFA) |
| 0 (0%) 09-01 21:46 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 11.93 |
| Resistance 1: | 10.21 |
| Pivot price: | 10.15 |
| Support 1: | 10.14 |
| Support 2: | 10.10 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.010 |
| Book Value | -0.220 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Tue, 01 Sep 2026
FDA Approves Ropeginterferon Alfa-2b in Essential Thrombocythemia - The American Journal of Managed Care
Tue, 01 Sep 2026
Alfa Romeo, Official Car of Genoa International Boat Show - Media Stellantis
Mon, 31 Aug 2026
Alfa’s 2026 Giulia Quadrifoglio Is Over A Decade Old And Still Out-Handles A New M3 - Carscoops
Mon, 31 Aug 2026
FDA Approves Ropeginterferon Alfa-2b-njft (Besremi) for Essential Thrombocythemia - biopharminternational.com
Mon, 31 Aug 2026
FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia - Targeted Oncology
Mon, 31 Aug 2026
FDA Approves BESREMi for Adults with Essential Thrombocythemia - Oncology Nursing News
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
